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Summary K562 leukaemia cells were selected for resistance using 0.5 tiLM etoposide (VP-16). Cloned K/VP.5
cells were 30-fold resistant to growth inhibition by VP-16 and 5- to 13-fold resistant to m-AMSA, adriamycin
and mitoxantrone. K/VP.5 cells did not overexpress P-glycoprotein; VP-16 accumulation was similar to that in
K562 cells. VP-16-induced DNA damage was reduced in cells and nuclei from K/VP.5 cells compared with
K562 cells. Topoisomerase II protein was reduced 3- to 7-fold and topoisomerase IIa and topoisomerase IIP
mRNAs were each reduced 3-fold in resistant cells. After drug removal, VP-16-induced DNA damage
disappeared 1.7 times more rapidly and VP-16-induced DNA-topoisomerase II adducts dissociated 1.5 times
more rapidly in K/VP.5 cells than in K562 cells. ATP (I mM) was more effective in enhancing VP-16-induced
DNA damage in nuclei isolated from sensitive cells than in nuclei from resistant cells. In addition, ATP
(0.3-5 mM) stimulated VP-16-induced DNA-topoisomerase II adducts to a greater extent in K562 nuclei than
in K/VP.5 nuclei. Taken together, these results indicate that resistance to VP-16 in a K562 subline is associated
with a quantitative reduction in topoisomerase II protein and, in addition, a distinct qualitative alteration in
topoisomerase II affecting the stability of drug-induced DNA-topoisomerase II complexes.
DNA topoisomerase II (topoisomerase II) is a nuclear
matrix-associated DNA-binding protein responsible for tran-
sient cleavage of DNA, allowing the passage of DNA double
strands through formed DNA breaks to relieve torsional
stress during replication and transcription (Wang, 1985; Liu,
1989; Osheroff, 1989). Topoisomerase II also allows for
separation of daughter DNA strands during mitosis and is
thought to play a role in recombinational events (Wang,
1985). Topoisomerase II is a target for a number of clinically
effective antineoplastic agents including m-AMSA, doxo-
rubicin, mitoxantrone, VM-26 and VP-16 (Chen et al., 1984;
Tewey et al., 1984a,b; Zwelling, 1985; Minford et al., 1986;
Zhang, 1990). These drugs interfere with topoisomerase II
activity by stabilising topoisomerase II/DNA binding and
strand breakage, a result of blockade of the religation/
resealing reaction which follows topoisomerase 1I-mediated
strand breakage (Chen et al., 1984; Nelson et al., 1984). Drug
resistance associated with alterations in the level, activity
and/or phosphorylation state of topoisomerase II has been
reported in both murine and human malignant cell lines
selected for resistance in the presence of topoisomerase II
inhibitors (Glisson et al., 1986; Odaimi et al., 1986; Pommier
et al., 1986a,b; Danks et al., 1987; 1988; Drake et al., 1987;
Per et al., 1987; Davies et al., 1988; Ferguson et al., 1988;
Deffie et al., 1989; Harker et al., 1989; 1991; Roberts et al.,
1989; Zwelling et al., 1989; Fernandes et al., 1990; Matsuo et
al., 1990; Charcosset et al., 1991; Cole et al., 1991; Friche et
al., 1991; Long et al., 1991; Sugawara et al., 1991; Takano et
al., 1991; Webb et al., 1991; Patel & Fisher, 1993; Sullivan et
al. 1993). In several resistant cell lines, quantitative reduction
of topoisomerase II expression has been correlated with the
level of drug resistance in the absence of alterations of drug
transport and may represent the major or sole determinant
for resistance (Per et al., 1987; Cole et al., 1991; Long et al.,
1991; Takano et al., 1991; Webb et al., 1991). In other cell
lines selected for resistance in the presence of VP-16, VM-26,
anthracyclines or mitoxantrone, there is not only reduced
topoisomerase II expression but also reduced drug accumula-
tion, often (but not always) correlated with amplification of
the mdrl gene and overexpression of the 150-180 kDa P-
glycoprotein drug efflux pump (Ferguson et al., 1988; Deffie
et al., 1989; Matsuo et al., 1990; Politi et al., 1990; Friche et
al., 1991; Long et al., 1991; Kamath et al., 1992; de Jong et
al., 1993). Qualitative alterations in topoisomerase II activity
have also been reported (Danks et al., 1988; Zwelling et al.,
1989; Sullivan et al., 1989; 1993) in cell lines selected for
resistance in the presence of topoisomerase II inhibitors
(Gupta et al., 1983; Beran & Anderson, 1987; Danks et al.,
1987; Sullivan et al., 1993) In several of these resistant
human leukaemia cell lines point mutations have been
identified within or near nucleotide-binding consensus
sequences of the topoisomerase II gene (Bugg et al., 1991;
Hinds et al., 1991; Lee et al., 1992; Danks et al., 1993; Chan
et al., 1993). Point mutations have also been identified near
the active-site tyrosine 804 in resistant cell topoisomerase IIa
obtained from CCRF CEM cells selected for resistance in the
presence of VM-26 or VP-16 (Danks et al., 1993; Patel &
Fisher, 1993). In resistant cell lines exhibiting qualitative
changes in topoisomerase II activity there are neither quan-
titative alterations in topoisomerase II expression nor
changes in drug accumulation or overexpression of P-
glycoprotein. Thus, stable resistance to topoisomerase II
inhibitors can be manifest as (1) altered topoisomerase II
expression alone or (2) together with the P-glycoprotein mul-
tiple drug resistance phenotype or (3) as a result of a muta-
tion(s) resulting in a qualitative change in topoisomerase II
activity.
In this paper, we describe a subline of human leukaemia
K562 cells selected for resistance in the presence of VP-16
which has no alterations in drug accumulation compared
with sensitive K562 cells. These stably resistant K/VP.5 cells
have decreased expression of topoisomerase II mRNA and
protein compared with parental K562 cells. In addition to
this quantitative decrease in topoisomerase II, K/VP.5 cells
exhibit qualitative changes in topoisomerase II activity
related to stability of drug-induced topoisomerase II-DNA
complexes and alterations in nucleotide dependency for for-
mation of topoisomerase II-DNA complexes. Thus, resis-
tance to topoisomerase II inhibitors in this novel resistant
cell line is due to both qualitative and quantitative changes at
the level of topoisomerase II.
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Materials and methods
Drugs and chemicals
[U-3H]VP-16 was obtained from Moravek Biochemicals
(Brea, CA, USA) and was more than 95% radiochemically
pure as measured by high-performance liquid chromato-
graphy (Sinkule & Evans, 1984). [2-'4C]Thymidine (53 mCi
mmol'I), [U-_4C]leucine, [methyl-3H]thymidine (20 Ci mmol-)
and [x-32P]dCTP were obtained from New England Nuclear
(Boston, MA, USA). VP-16 and VM-26 were provided by
Bristol-Myers Squibb (Wallingford, CT, USA). Amsacrine,
adriamycin and mitoxantrone were obtained from the Drug
Investigational Branch of the National Cancer Institute. Vin-
cristine, vinblastine, podophyllotoxin, camptothecin and pro-
teinase K were obtained from Sigma (St Louis, MO, USA).
Water-insoluble drugs were prepared in dimethylsulphoxide
(DMSO) such that solvent concentrations did not exceed 1%
in the culture medium or buffer after drug treatment. DMSO
was also included in control flasks at equivalent levels. Pro-
tein dye reagent and agarose were purchased from BioRad
Laboratories (Richmond, CA, USA). L.F. Liu, Johns Hop-
kins University, Baltimore, MD, USA, generously provided
antisera (IID3) against human DNA topoisomerase II as well
as the DNA topoisomerase II cDNA probe (ZI169) con-
tained in the plasmid pCI5 and the DNA topoisomerase I
cDNA probe contained in the plasmid pSH5-13. F.H. Drake,
SmithKline Beecham Laboratories (King of Prussia, PA,
USA), kindly provided a sample of purified DNA topoiso-
merase II.
Cells, media and incubation conditions
Human leukaemia K562 cells were grown in suspension cul-
ture in Dulbecco's modified Eagle medium (DMEM) plus
10% fetal calf serum and L-glutamine. L1210 cells were
grown in DMEM, 10% horse serum and L-glutamine. Resis-
tant K/VP.5 cells were selected by first periodic and then
continuous exposure of K562 cells to 0.5 gM VP-16 for 1
year, after which clones were isolated by limiting dilution
(Norman & Thompson, 1977). The K/VP.5 clone had a
doubling time of 22 h compared with the parental K562
doubling time of 18 h. The resistant clone has been stably
resistant in the absence of drug for 2 years. Cytogenetic
analysis indicated that both parental and resistant cells were
hyperdiploid. No homogeneously staining regions or double
minute chromosomes were present in K/VP.5 cells.
Drug-induced growth inhibition and drug accumulation
Log-phase sensitive and resistant cells were adjusted to
1 x 1O' cell ml-' and incubated with various concentrations
of a number of drugs for a period of 48 h, after which cells
were counted on a model ZBF Coulter counter (Coulter Elec-
tronics, Hialeah, FL, USA). The extent of growth (beyond
the starting concentration of 1 x I05 cells ml-') in drug-
treated vs control cells was ultimately expressed as per cent
inhibition of control growth. The 50% growth-inhibitory
concentration for each drug in each cell line was calculated
from replicate dose-response curves generated from separate
experiments.
For drug accumulation studies, K562 and K/VP.5 cells
were suspended in a pH 7.4 buffer (buffer L) of 110 mM
sodium chloride, 5 mM potassium chloride, 1 mM magnesium
chloride, 5 mM sodium dihydrogen phosphate, 25 mM 4-(2-
hydroxy-ethyl)-1-piperazineethanesulphonic acid and 10 mM
glucose, at a final concentration of 0.5 x I07 cells ml-'. Cells
were stirred in specially designed flasks by revolving Teflon
paddles in a 37°C water bath, as described previously
(Yalowich, 1987). One millilitre portions of cell suspension
containing [3H]VP-16 were periodically injected into ten
volumes of 0.85% sodium chloride solution at 0°C. Cell
fractions were then separated by centrifugation and washed
twice with 0.85% sodium chloride at 0°C. The washed pellet
was drawn up into a plastic pipette tip, extruded onto a
polyethylene tare and dried overnight at 70°C. The dried
pellets were weighed, placed in a glass scintillation vial and
dissolved in 0.25 ml of 1 M potassium hydroxide for 90 min
at 70°C. The digest was neutralised with 0.25 ml of 1 M
hydrochloric acid; 4 ml of aqueous counting scintillant
(Amersham Corp., Arlington Heights, IL, USA) was added,
and radioactivity was determined by liquid scintillation coun-
ting. Results yield cellular drug content expressed as nmol
per g dry weight. Intracellular water per g dry weight was
determined from the difference between the wet and dry
weights of cell pellets minus the ['4C]inulin space, as des-
cribed elsewhere (Yalowich & Goldman, 1984). Molar intra-
cellular drug concentration was then determined from the
molar content of cell VP-16 and the intracellular water
volume.
DNA damage assays
For DNA damage experiments, K562 and K/VP.5 cells were
labelled for 48 h with [2-'4C]thymidine (0.02piCiml-1). L1210
cells were labelled for 16 h with [methyl-3H]thymidine
(0.1ILCi ml-'). Unlabelled thymidine was added to allow for
a final thymidine concentration of 1 tLM in the culture
medium.
Isolated nuclei were prepared by washing '4C-labelled
whole cells in an ice-cold buffer A (pH 6.4) containing 1 mM
potassium dihydrogen phosphate, 5 mM magnesium chloride,
150 mM sodium chloride and 1 mM EGTA (Filipski & Kohn,
1982). The cells were resuspended in 1 ml of this buffer, and
an additional 9 ml of buffer A containing 0.3% Triton X-100
was added to lyse the cells. After incubation on ice for
30 min, 40 ml of buffer A was added, and nuclei were
pelleted by centrifugation at 1,000 r.p.m. for 10 min in an
IEC model HN-SII tabletop centrifuge. Nuclei density was
adjusted to 1 x 106 ml-' in cold buffer. After warming at
37C for 15 min, the nuclei were treated with VP-16 and
other agents in the presence or absence of 1 mM ATP and
processed for measurement of DNA damage as described
below.
Drug-mediated DNA damage was assessed using the
alkaline elution technique for high-frequency single-strand
breaks (Kohn et al., 1976). Intact K562 and K/VP.5 cells
previously labelled with [2-'4C]thymidine were suspended at
5 x 105 cells ml-l in buffer A. These cells were incubated with
various concentrations of VP-16 and other agents for 30 min
at 37°C. L1210 cells (5 x 105) containing [3H]DNA which
received 1,500 rad irradiation were added as internal stan-
dards to 7.5 x 105 drug-treated K562 cells containing
['4C]DNA. After two washings in cold buffer A, cells were
layered onto a polyvinyl chloride filter (pore size 0.8lsm;
Gelman Sciences, Ann Arbor, MI, USA) and lysed with a
solution of 2% sodium dodecyl sulphate, 10 mM disodium
EDTA and 0.5 mgml' proteinase K. The DNA was eluted
from the filter with tetrapropylammonium hydroxide,
pH 12.1. The elution flow rate was 0.16 mlmin-', with a
fractional interval of 5 min. Cells containing [3H]DNA were
irradiated on ice with a '37Cs source (Mark Irradiator; J.L.
Sheppard and Associates, Glendale, CA, USA). The fre-
quency of VP-16- and other drug-induced DNA single-strand
breaks (SSBs) was quantitated as the fraction of ['4C]DNA
remaining on the filter when either 60% or 75% of the
3H-labelled internal standard DNA remains. A calibration
curve for relating the frequency ofVP-16-induced DNA SSBs
to a corresponding effect of radiation (radiation equivalent
DNA damage) using '4C-labelled cells was obtained by plot-
ting rads vs [14C]DNA retention at 60% or 75% retention of
the [3H]DNA internal standard.
Determination of DNA-protein cross-link (DPC) fre-
quency was accomplished as previously described (Ross et
al., 1979). Aliquots of ['4C]thymidine-labelled K562 and K/
VP.5 cells (5 x 10 ml-') or nuclei (1 x 106ml-'), drug-
treated or controls, were irradiated on ice with 3,000 rad
prior to elution, as were internal control 3H-labelled L1210
cells. Cells or nuclei were layered onto polyvinyl-
chloride-acrylic co-polymer filters (Metricel DM-800; Gel-
man Sciences) along with 7.5 x 105 internal control cells, andVP-16 RESISTANCE AND ALTERED DNA TOPOISOMERASE II 689
lysed with 5 ml of a solution of 0.2% Sarkosyl, 2 M sodium
chloride, 0.04 M disodium EDTA, pH 10, which was allowed
to flow through the filters by gravity, as was a 3 ml addition
of 0.04M disodium EDTA, pH 10. DNA was eluted with
tetrapropylammonium hydroxide, pH 12.1, at a flow rate of
0.035 ml min-'. Fractions were collected at 90 min intervals
for 12 h. DPC frequencies were calculated according to the
bound-to-one terminus model (Ross et al., 1979):
DPC (rad equivalents) = [(1- r) --(1 -ro) -JPB
where ro and r are the fractional filter retentions of DNA
extrapolated to zero time from [14C]thymidine-labelled con-
trol and drug-treated cells (or nuclei) respectively and PB is
the radiation dose administered (3,000 rad). The greater the
DNA retention of drug-treated cells relative to controls, the
greater the DPC frequency.
DNA topoisomerase II-DNA covalent complexformation
assay-intact cells andnuclei
Mid-log cells (1.5-2.0 x IO cellsml-') were labelled over-
night with 0.5itCi ml-' [methyl-3H]thymidine (0.5 Ci mmol-')
and 0.1ILCi mlh- [U-_4C]leucine (318 mCimmol-') in DMEM
containing 5% FBS. Cells were then pelleted and resus-
pended in fresh DMEM/5% FBS and incubated for 1 h at
37°C. For experiments measuring the stability of topois-
omerase II-DNA covalent complexes after VP-16 removal,
cells were washed, resuspended in buffer L and equilibrated
to 37°C. VP-16 was added to 20-200 lM and incubation
continued for an additional 15 min at 37C. Cells were
pelleted for 90 s at 2,400g, washed with ice-cold buffer L and
repelleted. Cells were resuspended to 1 x 106mI- in L buffer
at 37°C. At selected intervals, 1 x 106 cells were removed and
added to 10 ml of ice-cold PBS and held on ice until all time
points were collected. Cells were pelleted, lysed, cellular
DNA sheared and protein-DNA complexes precipitated
with SDS and potassium chloride as described by Zwelling et
al. (1989). For experiments examining the effect of ATP on
VP-16-induced stabilisation of topoisomerase II-DNA cleav-
able complexes, nuclei were isolated from cells as described
above and adjusted to 2 x 106 nuclei ml1' in buffer A (pH 7.4)
containing 0.5 mM ATP. After prewarming at 37°C for 5 min,
200tLM VP-16 or 0.4% DMSO (control) was added and
incubation continued at 37°C for an additional 15 min.
Nuclei were pelleted, lysed, cellular DNA sheared and com-
plexes precipitated with SDS-potassium chloride exactly as
for whole cells.
Topoisomerase II catalytic activity
Topoisomerase II-containing extracts of nuclei were prepared
from 1-2 x 108 K562 and K/VP.5 cells as previously des-
cribed (Danks et al., 1988). When the aqueous volume con-
tributed by the nuclei is taken into consideration, the final
sodium chloride concentration of the nuclear extracts varied
between preparations from 0.7 to 0.85 M. Crithidiafasiculata
was labelled with 8 ZCi ml-' [methyl-3H]thymidine and
kinetoplast mitochondrial DNA (kDNA) isolated as pre-
viously described (Sahai & Kaplan, 1986). Topoisomerase II
catalytic activity was measured by decatenation of kDNA
(Sullivan et al., 1989). Each 40IlI assay contained 50 mM Tris
(pH 7.5), 85 mM potassium chloride, 10mM magnesium
chloride, 0.5 mM DTT, 0.5 mM disodium EDTA, 30ygml-'
BSA, 0-1 mM ATP, 0-100MM VP-16 (in DMSO), 1 tg
(10,000 c.p.m.) of 3H-labelled kDNA and 0-3tig of nuclear
extract topoisomerase II from K562 or K/VP.5 cells. After
incubation at 30°C for 30 min, reactions were stopped by
addition of 10ptl of 2.5% SDS and were then centrifuged for
15 min at 8,000g at 25°C. Duplicate 10gl samples from each
tube were counted in a liquid scintillation spectrometer in
3.5 ml of Ecolite (ICN Biochemicals, Irvine, CA, USA).
Decatenation was quantitated subsequent to subtraction of
counts found in DMSO controls in the absence of nuclear
extract topoisomerase II.
Western blots ofcell lysates
Lysates from 2-5 x 106 K562 or K/VP.5 cells were prepared
by the addition of an equal volume of 2 x gel loading buffer
(0.1 M Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 0.5 M
P-mercaptoethanol). Lysates were boiled for 5 min, sonicated
to reduce viscosity and protein content determined using the
BioRad protein assay. Samples containing 10jig were electro-
phoresed through 6% SDS-polyacrylamide gel (Laemmli,
1970) and electroblotted at 400 mA overnight to nitrocel-
lulose (Towbin et al., 1979) using a Hoefer (San Franscisco,
CA, USA) Transfor apparatus. Blots were incubated with
human topoisomerase II-specific rabbit antiserum, IID3
(from L.F. Liu), affinity-purified topoisomerase IIa-specific
antibody FHD22 (Webb et al., 1993) or affinity-purified
topoisomerase IIP-specific antibody FHD21 (Chung et al.,
1989). The affinity-purified, isoform-specific antibodies were
provided by F.H. Drake (SmithKline Beecham). Bound
antibodies were detected using alkaline phosphatase-con-
jugated goat anti-rabbit IgG and the ProtoBlot Western Blot
AP System of Promega Biotech (Madison, WI, USA). Levels
of topoisomerase II were quantitated by scanning positive
films of photographed blots using a Visage 110 image
analyser (Ann Arbor, MI, USA).
Northern blot analysis ofcellular RNAs
Total cellular RNA was isolated from 1-2 x 108 K562 and
K/VP.5 cells (Chomczynski & Sacchi, 1987). RNA (10fig)
was electrophoresed through 1.2% agarose gels containing
0.3 M formaldehyde, 40 mM 3-(N-morpholono)propane sul-
phonic acid (MOPS) pH 7.0, 10 mM sodium acetate tri-
hydrate, 1 mM EDTA, transferred to Nytran (Schleicher &
Schuell, Keene, NH, USA) by capillary blotting overnight,
baked for 2 h at 80°C and hybridised using standard tech-
niques (Maniatis et al., 1982). Specific RNAs were detected
by autoradiography at - 70°C using intensifying screens and
Kodak XAR-5 X-ray film.
Probe synthesis and labelling
The human topoisomerase IIo cDNA probe (ZI169) con-
tained in the plasmid pC15 was provided by L.F. Liu. A
human topoisomerase II3 cDNA probe, synthesised by
polymerase chain reaction (PCR) amplification using topoiso-
merase Ilp-specific primers, was provided by D.P. Suttle (St
Jude Children's Research Hospital, Memphis, TN, USA).
The 12-microglobulin cDNA probe in plasmid P132m was
provided by K.B. Tan. Cloned inserts were removed from
plasmids pC15 and P12m by digestion with restriction
enzymes and isolation on agarose gels. cDNA fragments
were used as templates for probe synthesis using Klenow
fragment, [_-32P]dCTP (3,000 Cimmol-') and random primer
initiation (Feinberg & Vogelstein, 1983).
Results
Drug accumulation andgrowth-inhibitory effects in sensitive
and resistant cells
The K/VP.5 subline is 30-fold resistant to the 48 h growth-
inhibitory effects of the selecting agent VP-16, and equally
cross-resistant to VM-26 (Table I). In addition, there was
lower (5- to 13-fold) cross-resistance to m-AMSA, adria-
mycin and mitoxantrone, three other agents that are known
to inhibit topoisomerase II. K/VP.5 cells cultured in the
absence of VP-16 have maintained this level of resistance for
2 years. In contrast, K/VP.5 cells were not cross-resistant to
the microtubule inhibitors vincristine, vinblastine and
podophyllotoxin, the antimetabolite arabinosyl cytosine or to
the DNA topoisomerase I inhibitor camptothecin (Table I).
Figure 1 indicates that the steady-state concentrations of
VP-16 in K/VP.5 cells were slightly higher than in parental
K562 cells when cells were exposed to 2.5-2011mM [3H]VP-16.690 M.K. RITKE et al.
Table I Cross-resistance of K/VP.5 cells to anti-cancer agents
Anti-cancer IC50 values (nM)a Relative
agent K562 K/VP.5 resistance'
VP-16 121 ± 48 (21)C 3640 1617 (21) 30
VM-26 10.3 ± 0.5 (4) 369 63 (4) 36
Amsacrine 41.4 ± 22.3 (8) 524 ± 240 (8) 12.7
Adriamycin 38.6 ± 10.8 (7) 178 ± 71 (8) 4.8
Mitoxantrone 14.7 ± 4.8 (5) 66.0 ± 21.4 (5) 4.5
Camptothecin 5.2 ± 0.9 (4) 5.9 ± 1.5 (4) 1.1
Vinblastine 8.2 ± 5.2 (9) 5.7 ± 2.8 (13) 0.7
Vincristine 5.8 ± 2.7 (7) 4.1 ± 1.1 (5) 0.7
Podophyllotoxin 7.6 ± 7.9 (7) 9.1 ± 4.4 (4) 1.2
ARA-C 4.7 ± 0.2 (3) 6.8 ± 1.5 (3) 1.4
850% inhibitory concentration ina48 hgrowthinhibitionassay.bIC50 ofK/VP.5
cells divided by that of the parental K562 cell line. cMean ± s.d.; numbers in
parentheses, numbers ofexperiments run on different days.
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Figure 1 Steady-state cellular concentrations of VP-16 in K562
(0) and K/VP.5 (U) cells exposed to 2.5-20 1M [3H]VP-16.
Steady-state concentrations of VP-16 were achieved within
10- 15 min, regardless of extracellular VP-16 concentration. For
each experiment, 3-5 measurements at steady state were obtained
at each drug concentration. Points, mean of three separate
experiments; bars, s.d.
These results are consistent with those previously reported
(Beran & Anderson, 1987), in which accumulation of m-
AMSA was slightly increased in HL-60 cells selected for
resistance in the presence of m-AMSA. Accounting for intra-
cellular water content (Yalowich & Goldman, 1984), which
was 5.19 ± 0.74 and 5.37 ± 0.13 ml g-' dry weight for K/VP.5
and K562 cells respectively, the intracellular VP-16 concen-
tration was 22.2 JAM and 30.2 tim for K562 and K/VP.5 cells
respectively, when the intracellular VP-16 concentration was
20 JAM. These results demonstrate that VP-16 does not con-
centrate extensively within cells and suggests that decreased
drug accumulation does not play a role in resistance to
VP-16 in K/VP.5 cells. In addition, averaging results from
4-7 separate experiments, there were no significant differ-
ences in VP-16 unidirectional efflux in sensitive and resistant
cells loaded to steady-state drug concentrations in the pre-
sence of 5 JAM [3H]VP-16 (t1/2 = 103 ± 12 s and 108 ± 2 s for
K562 and K/VP.5 cells respectively) using methods previous-
ly reported (Yalowich, 1987). Finally, using the C219 mono-
clonal antibody, there was no overexpression of P-glyco-
protein (180 kDa) in cell membranes from K/VP.5 compared
with K562 cells (M. Meyers & J.C. Yalowich, unpublished
data).
Drug-induced DNA single-strand breaks and DNA-protein
cross-linking
DNA single-strand break frequency was reduced in K/VP.5
cells compared with parental K562 cells when these two lines
were incubated with varying concentrations of VP-16 (Figure
2). A similar reduction in single-strand breaks was observed
in resistant cells in the presence of m-AMSA and adriamycin
(not shown). VP-16 (10-100 AM)-induced single-strand
breaks were also reduced in isolated K/VP.5 nuclei compared
with K562 nuclei (results not shown). In three separate
experiments in which nuclei were incubated with 10OJM m-
AMSA, the single-strand break frequency was 1857 ± 238
and 671 ± 46 radiation equivalents (mean ± s.e.) for K562
and K/VP.5 nuclei respectively. When the DNA
topoisomerase I inhibitor camptothecin (0.1-1.0J1M) was
added to isolated nuclei from K562 and K/VP.5 cells, there
was no difference in drug-induced DNA strand break fre-
quency (not shown). Finally, DNA-protein cross-linking
(DPC) induced by VP-16, VM-26 and m-AMSA was
decreased in K/VP.5 compared with K562 cells (Figure 3).
Topoisomerase II catalytic activity
Decatenation activity of nuclear extract topoisomerase II
(O-2 JAg) isolated from K562 and K/VP.5 cells indicated that
topoisomerase II catalytic activity was reduced 5- to 7-fold in
resistant compared with sensitive cells as measured by the
amount of protein required for 50% decatenation (Figure 4).
Since decreased topoisomerase II levels could account for
reduced topoisomerase II catalytic activity, the next set of
experiments examined topoisomerase II expression in K562
and K/VP.5 cells.
Topoisomerase II levels: Western blot analysis
The amount of topoisomerase II in whole-cell lysates and in
0.8 M sodium chloride nuclear extracts from K562 and K/
VP.5 cells was determined by Western blotting utilising rab-
bit IID3 antiserum to human DNA topoisomerase II (Figure
5). Two bands were observed in the lane containing purified
topoisomerase II from P388 leukaemia cells (Drake et al.,
1987) as well as in lanes corresponding to K/VP.5 nuclear
extracts. The molecular weights of these bands were
170 ± 3 kDa and 179 ± 3 kDa (mean ± s.e.; n = 5), corres-
ponding to previously characterised topoisomerase IIa and
topoisomerase II,B isoforms of this enzyme respectively
(Chung et al., 1989; Drake et al., 1989). A pronounced
reduction in the level of topoisomerase II in the lower
molecular weight band (topoisomerase Ila) in both whole-cell
lysates and nuclear extracts was observed in resistant K/VP.5
cells. Levels of topoisomerase IlI were quantitated by den-
sitometric scanning of immunolabelled 170 kDa bands from
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whole-cell lysates or nuclear extracts. The topoisomerase II
signals (area under scanned peak) obtained with various
amounts of K562 protein served as a standard curve from
which signals for K/VP.5 were quantitated. Using whole-cell
lysates, we observed a 7.8- ± 2.3-fold reduction in the level of
topoisomerase II (Mr 170,000) in K/VP.5 compared with
K562 cells (mean ± s.e., from three separate lysate prepara-
tions). In nuclear extracts there was a 4.5-fold decrease in the
level of topoisomerase II in K/VP.5 compared with K562
cells (not shown). The higher molecular weight band
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Figure 2 DNA single-strand breaks in K562 (0) and K/VP.5
(@) cells treated for 30 min in the presence of various concentra-
tions of VP-16. A calibration curve for relating the frequency of
VP-16-induced single-strand breaks to a corresponding effect of
radiation (radiation equivalent DNA damage) was obtained by
plotting rads vs ['4C]DNA retention at 75% retention of the
[3H]DNA internal standard. Points, mean of 5-10 separate
experiments; bars, s.e.
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(topoisomerase II,B) showed much less staining in both sen-
sitive and resistant cell lysates and nuclear extracts and could
not be accurately quantitated. However, we independently
quantitated levels of each topoisomerase II isoform by prob-
ing Western blots (not shown) of whole-cell lysates with
polyclonal antibodies that specifically recognise either to-
poisomerase Iat (antibody FHD22) or topoisomerase IIP
(antibody FHD21). Results from three independent blots
showed that topoisomerase IIha and topoisomerase Ip were
reduced 5.6- ± 1.6-fold and 2.7- ± 0.1-fold respectively
(mean ± s.e.) in K/VP.5 compared with K562 cells.
Topoisomerase II expression: Northern blot analysis oftotal
RNA
Using the human topoisomerase II cDNA probe (ZI169) and
total cellular RNA isolated from K562 and K/VP.5, we
observed a 2.9-fold reduction in expression of 6.2 kb
topoisomerase IIa RNA in K/VP.5 compared with parental
K562 cells (Figure 6). Co-hybridisation of a 132-microglobulin
(12 m) cDNA to the 1.0 kb P2 m RNA served as an internal
control for variable loading of RNA. Relative levels of
topoisomerase II mRNA were quantitated by densitometric
scanning of autoradiographs and corrected for 32 m levels.
Similar results have been obtained with four different RNA
preparations from K562 and K/VP.5 cells. There was a
similar 2.9-fold decrease in expression of topoisomerase IIP
mRNA in resistant compared with sensitive cells (Figure 7).
In contrast, there were no differences in expression of DNA
topoisomerase I mRNA in K562 and K/VP.5 cells (not
shown).
Reversal of VP-16-induced DNA damage
The rate of reversal of VP-16-induced single-strand break
damage was examined subsequent to a 30 min incubation of
K562 cells with 5 ytM VP-16 and of K/VP.5 cells with 40jiM
VP-16 in order to yield similar initial strand break frequen-
cies in both cell lines. Averaging results from five experiments
the initial DNA strand break frequency was 1436 ± 151 and
1130 ± 150 radiation equivalents for K562 and K/VP.5 cells
respectively (mean ± s.e.). After suspension of cells in drug-
free buffer at least seven determinations of remaining DNA
strand breaks were made during the next 40 min (results not
shown). The reversal of VP-16-induced DNA damage was
more rapid in resistant K/VP.5 cells compared with sensitive
K562 cells; averaging five separate paired experiments the t11/2
for reversal of DNA damage was 9.7 ± 1.5 and 16.1 +
1.9 min respectively (mean ± s.e.; P = 0.002, Student's paired
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Figure 3 DNA-protein cross-linking produced by VP-16, VM-
26, and mAMSA in K562 (open bars) and K/VP.5 (shaded bars)
cells. Cells were treated with drugs at 37°C for 30 min at the
indicated concentrations. DNA-protein cross-linking was quan-
titated by alkaline elution from polyvinyl chloride filters (0.8 tim)
and expressed as radiation equivalents (see Materials and
methods). Columns, mean of six separate experiements; bars, s.e.
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Figure 4 Decatenation of kinetoplast DNA as a function of
nuclear extract topoisomerase II. Salt (0.8 M)-extracted topoiso-
merase II from the nuclei of K562 and K/VP.5 cells was
incubated with 1 pg of 3H-labelled kinetoplast DNA in the
presence of 1 mm ATP for 30 min at 30C. Decatenation of DNA
was measured subsequent to centrifugal separation of catenated
from decatenated DNA as described in Materials and methods.692 M.K. RITKE et al.
t-test). Since the efflux rate of VP-16 from K562 and K/VP.5
cells does not differ (t112 2 min for both lines, see above),
and since VP-16 has been considered a non-intercalating
drug that does not bind directly to DNA, the more rapid
reversal of VP-16-induced DNA damage in K/VP.5 cells
compared with K562 cells suggests that resistant cells contain
an altered binding site(s) for VP-16: either an altered form of
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Figure 5 Topoisomerase II protein levels from K562 and K/
VP.5 cells. PBS-washed cells were lysed, sonicated, electro-
phoresed through SDS-polyacrylamide gels, and electroblotted
to nitrocellulose. The blot was labelled first with topoisomerase
1I-specific polyclonal antisera then alkaline phosphatase-con-
jugated goat anti-rabbit antibody as described in Materials and
methods. Shown are duplicate loadings of lO g of protein from
lysates of K562 and K/VP.5 cells (corresponding to lysates from
c. 1.5 x 105 cells). The last lane contains purified topoisomerase
II from P388 cells. Numbers to the right of the figures are
molecular size markers (in kDa).
topoisomerase II and/or an altered modulator of topoiso-
merase II activity. In addition, VP-16 efflux from both cell
lines (t1/2 t 2min) is more rapid than the rate of DNA
damage reversal from either cell line (tl/2= 9.7-16.1 min),
indicating that VP-16 transport is not rate limiting to the
process of reversal of VP-16-induced DNA damage. Hence,
these data suggest that altered stability of VP-16-induced
topoisomerase II-DNA covalent complexes in resistant cells
leads to more rapid reversal of DNA damage.
The specificity of VP-16-induced DNA damage and its
more rapid reversal in K/VP.5 compared with K562 cells was
revealed by experiments in which equivalent single-strand
breaks were introduced into the DNA of K562 and K/VP.5
cells by exposure of cells at 4°C to 1,500 rad of gamma-
irradiation. There was no difference in the rate of reversal of
DNA damage when cells were warmed to 37°C. In three
experiments the t112 for reversal of radiation-induced DNA
damage was l. ± 1.7 and 10.1± 2.2min (mean ± s.e.) in
K562 and K/VP.5 cells respectively. These results again are
consistent with the idea that VP-16-induced DNA damage
and its more rapid reversal in K/VP.5 cells is determined by
interaction with an intracellular target that is altered in these
resistant cells.
Stability of VP-16-induced topoisomerase II-DNA complexes
The stability of VP-16-induced topoisomerase II-DNA com-
plexes was measured subsequent to a 15 min incubation of
K562 cells with 20tM VP-16 and of K/VP.5 cells with
200 iM VP-16. At these VP-16 concentrations, the steady-
state level of topoisomerase II-DNA complex was similar
(within 15%) in sensitive vs resistant cells. After suspension
of cells in drug-free buffer, there was a more rapid dissocia-
tion of the topoisomerase II-DNA complex in resistant com-
pared with sensitive cells (Figure 8). In eight separate paired
experiments, the half-life for reversal of covalent complexes
of topoisomerase II-DNA in K/VP.5 cells averaged 6.2 +
0.3 min as compared with 9.0 ± 0.6 min for K562 cells
(mean + s.e.; P = 0.003, Student's paired t-test). Thus, a
significant reduction in stability of VP-16-induced topoiso-
merase II binding to DNA may be a factor in decreased
DNA damage and/or a more rapid rate of recovery from
DNA damage in resistant K/VP.5 cells.
K562 KNP.5
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Figure 6 Topoisomerase IIax mRNA levels in K562 and K/VP.5
cells. RNA was purified from mid-log phase cells and lO g was
electrophoresed through formaldehyde-containing agarose gels.
After transfer to a nylon membrane, RNAs were hybridised to
32P-labelled topoisomerase Ila and P2-microglobulin cDNA
probes, and autoradiographed as described in Materials and
methods. Topoisomerase Ila mRNA signals were corrected for
132-microglobulin levels. Averaging results from three separate
blots, there was a 2.91- ± 0.95-fold decrease in topoisomerase Ila
mRNA in K/VP.5 compared with K562 cells (mean ± s.d.;
P<0.02, Wilcoxon's signed-ranks test).
Figure 7 Topoisomerase Ip mRNA levels in K562 and K/VP.5
cells. RNA was purified, electrophoresed, immobilised and
hybridised to 32P-labelled topoisomerase IIP and P2-microglobulin
cDNA probes, and autoradiographed exactly as for Figure 7.
Topoisomerase I1p mRNA signals were corrected for P2-
microglobulin levels. Averaging results from three separate blots,
there was a 2.87- ± 0.62-fold decrease in topoisomerase I1p
mRNA in K/VP.5 compared with K562 cells (mean ± s.d.;
P<0.01, Wilcoxon's signed-ranks test).
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Table H Effects ofATP (I mM) on VP-16-induced single-strand break frequency and DNA-protein
cross-linking in sensitive K562 and resistant K/VP.5 nuclei
Type of Experimental Radiation equivalentsa
DNA lesion condition K562 (25 LM VP-16) K/VP.S (100 IM VP-16)
Single-strand Control 476± 46 (9) b 442 ± 30 (9)
breaks (SSBs) + ATP 1322 ± 86 (11) [277]C 770 ± 37 (4) [174]C DNA-protein Control 497± 28 (5) 301 ± 47 (5)
cross-links (DPCs) + ATP 1136 + 96 (5) [229]d 523 ± 83 (5) 174]d
aNuclei were incubated with the indicated concentrations of VP-16 for 30 min in the presence or
absence of I mM ATP, following which alkaline elution methodology was used for quantitation of
radiation equivalent SSBs and DPCs as described in Materials and methods. bData are expressed as
mean ± s.e.Numbersinparenthesesindicatethenumberofindividualexperimentsrunondifferentdays.
cNumbers in brackets represent the percentage increase in SSBs in the presence ofATP. The percentage increase in K562 nuclei is significantly greater than in K/VP.5 nuclei (P = 0.0001, Student's t-test
adjusted for non-equal sample variances). dNumbers in brackets represent the percentage increase in
DPCs in the presence ofATP. The percentage increase in K562 nuclei is significantly greater than in
K/VP.5 nuclei (P = 0.039, Student's paired t-test).
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Figure 8 Stability of topoisomerase 11-DNA covalent com-
plexes in VP-16-treated K562 and K/VP.5 cells. Cells were
prelabelled with [methyl-3H]thyrnidine and [u-'4Cqleucine, and
exposed to 201lm VP-16 (K562) or 20011m VP-16 (K/VP.5) for
15 min. Cells were washed free ofdrug, and at the indicated time
points (10s to 30min) aliquots were removed and potassium
chloride-SDS-precipitable complexes isolated as describedi in
Materials and methods. Results were normalised to 14C counts as
an internal standard for cell number, and are expressed relative
to potassium chloride-SDS-precipitable 3H counts recovered at
the end of VP-16 treatment (Omin).
Nucleotide-dependent VP-16-inducedformation ofsingle-strand
breaks, DNA-protein cross-links and topoisomerase Il-DNA
complexes
ATP (I1 mm) stimulates VP-16 (25tim)-induced SSBs almost
3-fold in nuclei isolated from K562 cells (Table II). In con-
trast, when the VP-16 concentration was increased to 100;1m to achieve a similar SSB frequency in K/VP.5 nuclei, ATP
enhanced drug-induced DNA damage less than 2-fold.
Similarly, ATP-mediated enhancement of VP-16-induced
DNA-protein cross-linking was significantly less in resistant
K/VP.5 than in sensitive K562 nuclei (Table II). Since
topoisomerase II catalytic activity is dependent on binding
(but not hydrolysis) of ATP (Osheroff, 1989), and since ATP
is known to stimulate VP-16-, m-AMSA-, ellipticine- and
5-iminodaunorubicin-induced DNA damage in isolated nuclei
from L1210 cells (Glisson et al., 1984; Pommier et al., 1984),
our results are consistent with the hypothesis that there is an
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Figure 9 Stimulation of topoisomerase 11-DNA covalent com-
plexes by ATP in nuclei isolated from VP-16-treated K562 and
K/VP.5 cells. Nuclei, from cells prelabelled with [methyl-
3H]thymidine and [U_'4C]leucine, were incubated for 15min in
the presence of 200 i1m VP-16 and various concentrations of
ATP. Potassium chloride-SDS-precipitable complexes were
isolated and the 3H-counts normalised to cell number using 14C as
an internal standard for cell number as described in Materials
and methods. Results are expressed as fold increase relative to
complexes isolated from cells incubated in the absence of VP-16
and ATP.
altered functional interaction of ATP with topoisomerase II
in resistant K/VP.5 cells. ATP stimulation of VP-16
(200pIm)-induced topoisomerase II-DNA covalent com-
plexes was less in K/VP.5 than in K562 nuclei (Figure 9). At
I mm ATP, covalent complex formation was increased 8-fold
for K562 cells but only 2-fold for K/VP.5 cells. In addition,
using a non-hydrolysable form of ATP, 5'-adenylyl-imidodi-
phosphate (I mm), there was less stimulation of VP-16-
induced topoisomerase II-DNA covalent complexes in
K/VP.5 nuclei (1.7- ± 0.2-fold) than in K562 (3.2- ± 0.4-fold)
nuclei (mean ± s.e., P<0.05; Student's paired t-test; data not
shown from four separate experiments). These data further
support a qualitative alteration in resistant cell topoisomerase
II affecting nucleotide-depende-nt VP-16-induced stabilisation
of topoisomerase 11-DNA complexes.
Topoisomerase IIcatalytic activity
After normalising for the difference in topoisomerase II pro-
tein in nuclear extracts obtained from sensitive and resistant
cells, 2-fold greater ATP concentration was required for 50%/
decatenation of 3H-labelled kinetoplast DNA using nuclear
extract topoisomerase II from K/VP.5 compared with K562
cells (Figure 10). When ATP concentration was fixed at
I mM, there was no significant difference in VP-16-induced694 M.K. RITKE et al.
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Figure 10 Effects of ATP on nuclear extract topoisomerase II
decatenation of kinetoplast DNA. Sodium chloride (0.8 M)-
extracted topoisomerase II from the nuclei of K562 and K/VP.5
cells was incubated with [Lg of 3H-labelled kinetoplast DNA in
the presence of 0 mm ATP for 30 min at 30°C. Decatenation
of kinetoplast DNA was measured subsequent to centrifugal
separation of catenated from decatenated DNA as described in
Materials and methods. In order to normalise for the 5-fold
differences in topoisomerase II levels in nuclear extracts from
these two cell lines, 0.36 tLg and 1.8 tig of nuclear extract protein
was used for K562 and K/VP.5 cells respectively. Points represent
the mean for 3-6 separate experiments; bars, s.e.
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Figure 11 Inhibition of topoisomerase II catalytic decatenation
activity by VP-16. Nuclear extract topoisomerase II from the
nuclei of K562 and K/VP.5 cells was incubated with 1 tg of
3H-labelled kineteoplast DNA in the presence of 1 mM ATP and
0-100 AM VP-16 for 30 min at 30°C. Decatenation of kinetoplast
DNA was measured as described in Figure 10 and Materials and
methods. Nuclear extract protein content was normalised for
differences in topoisomerase II content in K562 and K/VP.5 cells.
Inhibition of decatenation is expressed relative to decatenation
activity observed in the absence of VP-16. Points represent the
mean of four separate experiments; bars, s.e. The 50% inhibitory
concentrations were 22.0 ± 1.7 and 29.3 +4.1 JAM VP-16 for K562
and K/VP.5 cells respectively (P = 0.21).
inhibition of catalytic decatentation using nuclear extract
preparations from sensitive and resistant cells (Figure 11).
Discussion
The results presented in this study indicate that resistance to
VP- 16 and cross-resistance to other topoisomerase II
inhibitors in K/VP.5 cells is associated with alterations in
both the levels and the drug-induced DNA-binding activity
of topoisomerase II. Drug-induced DNA strand breaks,
DNA-protein cross-links and topoisomerase II catalytic
activity were reduced in K/VP.5 compared with K562 cells
and nuclei (Figures 2-4); these results correlate with the
reduction in levels of topoisomerase II protein (Figure 5) and
parallel the reduced levels of topoisomerase II mRNA
(Figure 6) in resistant compared with sensitive cells. Together
these results indicate a quantitative reduction in topoiso-
merase II expression in K/VP.5 cells. Previously, we per-
formed topoisomerase II immunoblot depletion experiments
which demonstrated that topoisomerase II from resistant
cells was not bound to DNA at VP-16 concentrations which
did induce topoisomerase II-DNA binding in sensitive cells
(Ritke & Yalowich, 1993). Similar topoisomerase II
immunoblot depletion experiments demonstrated qualitative
changes in topoisomerase Ila in a VP-16-resistant small-cell
lung cancer cell line which also exhibited quantitative
topoisomerase Ila alterations (Mirski et al., 1993). Together,
these results suggested qualitative alterations in
topoisomerase II in resistant K/VP.5 cells.
In order to better characterise qualitative alterations in
resistant cell topoisomerase II function in the present study,
we have used different VP-16 concentrations to achieve
similar levels of DNA damage or topoisomerase II-DNA
binding in sensitive vs resistant cells. In this manner we have
'normalised' for differences in topoisomerase II protein in
K562 and K/VP.5 cells. Under these experimental conditions,
the more rapid reversal of drug-induced DNA damage in
resistant K/VP.5 cells compared with K562 cells and the
attenuated effect of ATP on the stimulation of VP-16-
induced DNA strand breaks and DPC in nuclei from resis-
tant cells (Table II) strongly suggests that, in addition to the
quantitative changes reflected by reduced topoisomerase II
levels, there are qualitative alterations in topoisomerase II
function in K/VP.5 cells. This conclusion is further supported
by measurement of the stability of VP-16-induced topoiso-
merase II-DNA covalent complexes which was reduced in
K/VP.5 cells (Figure 8) and by the demonstration of a 2-fold
increase in ATP requirement for drug-induced K/VP.5 cell
topoisomerase I1-DNA binding and subsequent catalytic
activity (Figures 9 and 10).
The selection technique used to obtain K/VP.5 cells, inter-
mittent then continuous low-concentration (0.5pM) exposure
to VP-16, may relate to the dual phenotypic changes in this
cell line, i.e. quantitative and qualitative topoisomerase II
alterations. Multifactorial resistance characteristics have been
reported using intermittent topoisomerase II inhibitor ex-
posures (Long et al., 1991; Sugawara et al., 1991) or stepwise
increases in drug exposure (Ferguson et al., 1988; Matsuo et
al., 1990; de Jong et al., 1993) to select for resistant cell lines.
However, unlike those studies, the multifactorial resistance
reported here for K/VP.5 cells does not include reduced
intracellular drug accumulation. More discreet mutational or
regulatory changes in topoisomerase II have been observed in
cells treated with relatively high concentrations of topoiso-
merase II inhibitory drugs or with mutagens (Bugg et al.,
1991; Hinds et al., 1991; Lee et al., 1992; Chan et al., 1993;
Danks 1993). Even though our selection procedure used
relatively low concentrations of VP-16 (0.5 JAM), the fact that
K/VP.5 cells have retained 30-fold resistance to VP-16 in the
absence of drug for more than 2 years suggests that a stable
mutational alteration has occurred during the acquisition of
resistance.
At least two targets for mutation which are not mutually
exclusive may be considered as sources for the quantitative
and qualitative changes of topoisomerase II observed in the
K/VP.5 cell line. First, chronic VP-16 exposure may have
selected for an alteration in the topoisomerase II gene itself.
A mutation of the primary sequence could produce a less
stable mRNA, although the published nucleotide sequence
for topoisomerase II (Tsai-Pflugfelder et al., 1988) reveals no
known consensus mRNA stability determinants (Cleveland &
Yen, 1989). Alternatively, a mutation in the topoisomerase II
gene may also result in a RNA that is less efficiently trans-
cribed. The consequence of such a mutation would be a
reduction in topoisomerase II mRNA and decreased transla-
tion. Previously, we reported a reduction in the stability of
topoisomerase II mRNA in K/VP.5 cells that parallels the
reduction of topoisomerase II mRNA levels (Ritke &
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Yalowich, 1993). In addition, no change in topoisomerase II
transcription rate was observed in K/VP.5 compared with
K562 cells (Ritke & Yalowich, 1993). Mutations in the
coding sequence of the topoisomerase II gene could also
result in an alteration in the protein conformation or post-
translational modification of this enzyme, thus decreasing the
stability of its binding to DNA. Our data demonstrating an
attenuation of ATP stimulation of VP-16-induced
topoisomerase II-DNA binding in resistant cells correspond
to previously published data in VM-26-selected resistant
CCRF-CEM cells (Danks et al., 1989) and suggest a muta-
tion in or near ATP-binding domains of topoisomerase II
consistent with identified topoisomerase II mutations in
several other resistant cell lines (Bugg et al., 1991; Hinds et
al., 1991; Lee et al., 1992; Chan et al., 1993; Danks et al.,
1993) However, topoisomerase II cDNA sequence analysis
has revealed no changes in the region which includes consen-
sus nucleotide-binding domains (nucleotides 1134-1597)
comparing K562 and K/VP.5 cells (Ritke et al., submitted).
In addition, single-strand conformational polymorphism
analysis of topoisomerase II cDNA from K/VP.5 cells has
uncovered no evidence of mutations (Ritke et al., submitted).
Single-strand conformation polymorphism analysis has been
used previously to identify point mutations in topoisomerase
II cDNA from drug-resistant cell lines (Danks et al., 1993).
These results suggest that, despite the stable biochemical
changes in K/VP.5 topoisomerase II which implicate muta-
tions in the gene coding for this enzyme, there may be other
genetic changes in resistant cells that affect topoisomerase II
function. Sequence analysis of the entire coding sequence of
K/VP.5 and K562 topoisomerase II cDNA is under way and
will definitively reveal whether a point mutation(s) in K/VP.5
cells is related to qualitative and/or quantitative topoiso-
merase II alterations documented in the present work.
A second target for genetic alteration of VP-16-selected
K/VP.5 cells may be a regulator, effector or co-factor of
topoisomerase II. Topoisomerase II has been shown to be
phosphorylated in intact cells at serine and threonine residues
(Saijo et al., 1990; Kroll & Rowe, 1991; Cardenas et al.,
1992) and in vitro serves as a substrate for casein kinase II,
protein kinase C and p34cdc2 kinase (Ackerman et al., 1985;
1988; Sahyoun et al., 1986; Cardenas et al., 1992; Devore et
al., 1992; Corbett et al., 1993). In addition, the activity and
degree of phosphorylation of topoisomerase II has been
found to increase during cell cycle progression from GI to
G2-M phase (Heck et al., 1989; Woessner et al., 1991; Saijo
& Enomoto, 1992). These studies suggest a protein kinase as
a candidate topoisomerase II co-factor and a mutational
target in resistant K/VP.5 cells. Mutation and subsequent
altered activity of a protein kinase that phosphorylates
topoisomerase II might reduce the stability of this enzyme,
resulting in a decreased level of protein in resistant cells. A
change in topoisomerase II phosphorylation in resistant cells
might also influence ATP binding/hydrolysis and affect
catalytic activity, as has recently been demonstrated using
Drosophila topoisomerase II (Corbett et al., 1993). Altered
phosphorylation of topoisomerase II in resistant cells may
change the stability of topoisomerase II binding to DNA
such that VP-16 stabilisation of the protein-DNA complex is
compromised. Recent studies in this laboratory indicate that
topoisomerase II phosphorylation is reduced at least 2-fold in
K/VP.5 compared with parental K562 cells (Ritke et al.,
submitted). Therefore, altered topoisomerase II phosphoryla-
tion in K/VP.5 cells correlates with decreased VP-16-induced
topoisomerase II-DNA binding stability in these resistant
cells (Figure 8).
Based on studies presented here, we conclude that selection
for a low level of resistance to VP-16 resulted in a quan-
titative reduction of topoisomerase II expression as well as
distinct qualitative changes affecting VP-16-induced stability
of topoisomerase II-DNA binding. The multiple stable
phenotypic changes exhibited by the novel K/VP.5 cell line
provide an opportunity to increase our understanding of the
post-transcriptional and/or post-translational modifications
in DNA topoisomerase II which regulate its activity in
acquired drug resistance.
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gle-strand break; DPC, DNA-protein cross-links; SDS, sodium
dodecyl sulphate; DMSO, dimethylsuphoxide; EDTA, ethylene
diamine tetraacetic acid; EGTA, ethyleneglycol-bis-(P-aminoethyl
ether) N,N,N',N',-tetraacetic acid.
References
ACKERMAN, P., GLOVER, C.V.C. & OSHEROFF, N. (1985). Phos-
phorylation of DNA topoisomerase II by casein kinase II:
modulation of eukaryotic topoisomerase II activity in vitro. Proc.
Natl Acad. Sci. USA, 82, 3164-3168.
ACKERMAN, P., GLOVER, C.V.C. & OSHEROFF, N. (1988). Phos-
phorylation of DNA topoisomerase II in vivo and in total
homogenates of Drosophila Kc cells. The role of casein kinase II.
J. Biol. Chem., 263, 12653-12660.
BERAN, M. & ANDERSON, B.S. (1987). Development and charac-
terization of a human myelogenous leukemia cell line resistant to
4'-(9-acridinylamino)-3-methane-sulfon-m-anisidide. Cancer Res.,
47, 1897-1904.
BUGG, B.Y., DANKS, M.K., BECK, W.T. & SUTTLE, D.P. (1991). Ex-
pression of a mutant DNA topoisomerase II in CCRF-CEM
human leukemic cells selected for resistance to teniposide. Proc.
Natl Acad. Sci. USA, 88, 7654-7658.
CARDENAS, M.E., DANG, Q., GLOVER, C.V.C. & GASSER, S.M.
(1992). Casein kinase II phosphorylates the eukaryotic-specific
C-terminal domain of topoisomerase II in vivo. EMBO J., 11,
1785-1796.
CHAN, V.T.W., NG, S.-W., EDER, J.P. & SCHNIPPER, L.E. (1993).
Molecular cloning and identification of a point mutation in the
topoisomerase II cDNA from an etoposide-resistant chinese
hamster ovary cell lines. J. Biol. Chem., 268, 2160-2165.
CHARCOSSET, J.-Y., SAUCIER, J.-M. & JACQUEMIN-SABLON, A.
(1991). Reduced DNA topoisomerase II activity and drug-
stimulated DNA cleavage in 9-hydroxyellipticine resistant cells.
Biochem. Pharmacol., 37, 2145-2149.
CHEN, G.L., YANG, L., ROWE, T.C., HALLIGAN, B.D., TEWEY, K.M.
& LIU, L.F. (1984). Nonintercalative antitumor drugs interfere
with the breakage-reunion reaction of mammalian DNA
topoisomerase II. J. Biol. Chem., 259, 13560-13566.
CHOMCZYNSKI, P. & SACCHI, N. (1987). Single-step method of
RNA isolation by acid guanidinium thiocyanate-phenol-
chloroform extraction. Anal. Biochem., 162, 156-159.
CLEVELAND, D.W. & YEN, T.J. (1989). Multiple determinants of
eukaryotic mRNA stability. New Biol., 1, 121-126.
COLE, S.P.C., CHANDA, E.R., DICKE, F.P., GERLACH, J.H. & MIRSKI,
S.E.L. (1991). Non-P-glycoprotein-mediated multidrug resistance
in a small cell lung cancer cell line: evidence for decreased
susceptibility to drug-induced DNA damage and reduced levels of
topoisomerase II. Cancer Res., 51, 3345-3352.
CHUNG, T.D.Y., DRAKE, F.H., TAN, K.B., PER, S.R., CROOKE, S.T. &
MIRABELLI, C.K. (1989). Characterization and immunological
identification of cDNA clones encoding two human DNA
topoisomerase II isozymes. Proc. Natl Acad. Sci. USA, 86,
9431-9435.
CORBETT, A.H., FERNALD, A.W. & OSHEROFF, N. (1993). Protein
kinase C modulates the catalytic activity of topoisomerase II by
enhancing the rate of ATP hydrolysis: evidence for a common
mechanism of regulation by phosphorylation. Biochemistry, 32,
2090-2097.
DANKS, M.K., YALOWICH, J.C. & BECK, W.T. (1987). Atypical mul-
tiple drug resistance in human leukemic cell lines selected for
resistance to teniposide (VM-26). Cancer Res., 47, 1297-1301.696 M.K. RITKE et al.
DANKS, M.K., SCHMIDT, C.A., CIRTAIN, M.C., SUTTLE, D.P. &
BECK, W.T. (1988). Altered catalytic activity of and DNA
cleavage by DNA topoisomerase II from human leukemic cells
selected for resistance to VM-26. Biochemistry, 27, 8861-8869.
DANKS, M.K., SCHMIDT, C.A., DENEKA, D.A. & BECK, W.T. (1989).
Increased ATP requirement for activity of and complex forma-
tion by DNA topoisomerase II from human leukemic CCRF-
CEM cells selected for resistance to teniposide. Cancer Commun.,
1, 101-109.
DANKS, M.K., WARMOTH, M.R., FRICHE, E., GRANZEN, B., BUGG,
B.Y., HARKER, W.G., ZWELLING, L.A., FUTSCHER, B.W., SUT-
TLE, D.P. & BECK, W.T. (1993). Single-strand conformational
polymorphism analysis of the Mr 170,000 isozyme of DNA
topoisomerase II in human tumor cells. Cancer Res., 53,
1373-1379.
DAVIES, S.M., ROBSON, C.N., DAVIES, S.L. & HICKSON, I.D. (1988).
Nuclear topoisomerase II levels correlate with the sensitivity of
mammalian cells to intercalating agents and epipodophyllotoxins.
J. Biol. Chem., 263, 17724-17729.
DEFFIE, A.M., BATRA, J.K. & GOLDENBERG, G.J. (1989). Direct
correlation between DNA topoisomerase II activity and cytotox-
icity in adriamycin-sensitive and -resistant P388 leukemia cell
lines. Cancer Res., 49, 58-62.
DE JONG, S., LOOISTRA, A.J., DE VRIES, E.G.E., MULDER, N.H. &
ZIJLSTRA, J.G. (1993). Topoisomerase II as a target of VM-26
and 4'-(9-acridinylamino)methane-sulfon-m-anisidide in atypical
multidrug resistant human small cell lung carcinoma cells. Cancer
Res., 53, 1064-1071.
DEVORE, R.F., CORBETT, A.H. & OSHEROFF, N. (1992). Phosphory-
lation of topoisomerase II by casein kinase II and protein kinase
C: effects on enzyme-mediated DNA cleavage/religation and sen-
sitivity to the antineoplastic drug etoposide and 4'-(9-
acridinylamino)methane-sulfon-m-anisidide. Cancer Res., 52,
2156-2161.
DRAKE, F.H., ZIMMERMAN, J.P., MCCABE, F.L., BASTUS, H.F., PER,
S.R., SULLIVAN, D.M., ROSS, W.E., MATTERN, M.R., JOHNSON,
R.K., CROOKE, S.T. & MIRABELLI, C.K. (1987). Purification of
topoisomerase II from amsacrine-resistant P388 leukemia cells. J.
Biol. Chem., 262, 16739-16747.
DRAKE, F.H., HOFMANN, G.A., BARTUS, H.F., MATTERN, M.R.,
CROOKE, S.T. & MIRABELLI, C.K. (1989). Biochemical and phar-
macological properties of p170 and p180 forms of topoisomerase
II. Biochemistry, 28, 8154-8160.
FEINBERG, A.P. & VOGELSTEIN, B. (1983). A technique for
radiolabeling DNA restriction fragments to high specific activity.
Anal. Biochem., 137, 266-267.
FERGUSON, P.J., FISHER, M.H., STEPHENSON, J., LI, D.-H., ZHOU,
B.-S. & CHENG, Y.-C. (1988). Combined modalities of resistance in
etoposide-resistant human KB cell lines. Cancer Res., 48,
5956-5964.
FERNANDES, D.J., DANKS, M.K. & BECK, W.T. (1990). Decreased
nuclear matrix DNA topoisomerase II in human leukemia cells
resistant to VM-26 and m-AMSA. Biochemistry, 29, 4235-4241.
FILIPSKI, J. & KOfIN, K.W. (1982). Ellipticine-induced protein-
associated DNA breaks in isolated L1210 nuclei. Biochim.
Biophys. Acta, 698, 280-286.
FRICHE, E., DANKS, M.K., SCHMIDT, C.A. & BECK, W.T. (1991).
Decreased DNA topoisomerase II in daunorubicin-resistant Ehr-
lich ascites tumor cells. Cancer Res., 51, 4213-4218.
GLISSON, B., SMALLWOOD, S. & ROSS, W.E. (1984). Characterization
of VP-16-induced DNA damage in isolated nuclei from L1210
cells. Biochim. Biophys. Acta, 783, 74-79.
GLISSON, B., GUPTA, R., SMALLWOOD-KENTRO, S. & ROSS, W.
(1986). Characterization of acquired epipodophyllotoxin resist-
ance in a Chinese hamster ovary cell line: loss of drug-stimulated
DNA cleavage activity. Cancer Res., 46, 1934-1938.
GUPTA, R.S. (1983). Genetic, biochemical, and cross-resistance
studies with mutants of Chinese hamster ovary cells resistant to
the anticancer drugs, VM-26 and VP-16-213. Cancer Res., 43,
1568- 1574.
HARKER, W.G., SLADE, D.L., DALTON, W.S., MELTZER, P.S. &
TRENT, J.M. (1989). Multidrug resistance in mitoxantrone-
selected HL-60 leukemia cells in the absence of P-glycoprotein
overexpression. Cancer Res., 49, 4542-4549.
HARKER, W.G., SLADE, D.L., DRAKE, F.H. & PARR, R.L. (1991).
Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear
topoisomerase II catalytic activity and drug-induced DNA
cleavage in association with reduced expression of the topoiso-
merase II 13 isoform. Biochemistry, 30, 9953-9961.
HECK, M.M.S., HITTELMAN, W.N. & EARNSHAW, W.C. (1989). In
vivo phosphorylation of the 170-kDa form of eukaryotic DNA
topoisomerase II: cell cycle analysis. J. Biol. Chem., 264,
15161-15164.
HINDS, M., DEISSEROTH, K., MAYES, J., ALTSCHULER, E., JANSEN,
R., LEDLEY, F.D. & ZWELLING, L.A. (1991). Identification of a
point mutation in the topoisomerase II gene from a human
leukemia cell line containing an Amsacrine-resistant form of
topoisomerase II. Cancer Res., 51, 4729-4731.
KAMATH, N., GRABOWSKI, D., FORD, J., KERRIGAN, D., POM-
MIER, Y. & GANAPATHI, R. (1992). Overexpression of P-
glycoprotein and alterations in topoisomerase II in P388 mouse
leukemia cells selected in vivo for resistance to mitoxantrone.
Biochem. Pharmacol., 44, 937-945.
KOHN, K.W., ERICKSON, L.C., EWIG, R.A.G. & FRIEDMAN, C.A.
(1976). Fractionation of DNA from mammalian cells by alkaline
elution. Biochemistry, 14, 4629-4637.
KROLL, D.J. & ROWE, T.C. (1991). Phosphorylation of DNA
topoisomerase II in a human tumor cell line. J. Biol. Chem., 266,
7957-7961.
LAEMMLI, U.K. (1970). Cleavage of structural proteins during the
assembly of the head of bacteriophage. Nature, 227, 680-685.
LEE, M.-S., WANG, J.C. & BERAN, M. (1992). Two independent
amsacrine-resistant human myeloid leukemia cell lines share an
identical point mutation in the 170 kDa form of human
topoisomerase II. J. Mol. Biol., 223, 837-843.
LIU, L.F. (1989). DNA topoisomerase poisons as antitumor drugs.
Annu. Rev. Biochem., 58, 351-375.
LONG, B.H., WANG, L., LORICO, A., WANG, R.C.C., BRAITAIN, M.G.
& CASAZZA, A.M. (1991). Mechanisms of resistance to etoposide
and teniposide in acquired resistant human colon and lung car-
cinoma cell lines. Cancer Res., 51, 5275-5284.
MANIATIS, T., FRITSCH, E.F. & SAMBROOK, J. (1982). In Molecular
Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory
Press: Cold Spring Harbor, NY.
MATSUO, K., KOHNO, K., TAKANO, H., SATO, S., KIUE, A. &
KUWANO, M. (1990). Reduction of drug accumulation and DNA
topoisomerase II activity in acquired teniposide-resistant human
cancer KB cell lines. Cancer Res., 50, 5819-5824.
MINFORD, J., POMMIER, Y., FILIPSKI, J., KOHN, K.W., KERRIGAN,
D., MATTERN, M., MICHAELS, S., SCHWARTZ, R. & ZWELLING,
L.A. (1986). Isolation of intercalator-dependent protein-linked
DNA strand cleavage activity from cell nuclei and identification
as topoisomerase II. Biochemistry, 25, 9-16.
MIRSKI, S.E.L., EVANS, C.D., ALMQUIST, K.C., SLOVAK, M.L. &
COLE, S.P.C. (1993). Altered topoisomerase IfI in a drug-resistant
small cell lung cancer cell line selected in VP-16. Cancer Res., 53,
4866-4873.
NELSON, E.M., TEWEY, K.M. & LIU, L.F. (1984). Mechanism of
antitumor drug action: poisoning of mammalian DNA
topoisomerase II on DNA by 4'(9-acridinylamino)methane-
sulfone-m-anisidide. Proc. Natl Acad. Sci. USA, 81, 1361-1365.
NORMAN, M.R. & THOMPSON, E.B. (1977). Characterization of a
glucocorticoid-sensitive human lymphoid cell line. Cancer Res.,
37, 3785-3791.
ODAIMI, M., ANDERSON, B.S., MCCREDIE, K.B. & BERAN, M.
(1986). Drug sensitivity and cross-resistance of the 4'-(9-
acridinylamino)methane sulfon-m-anisidide-resistant subline of
HL-60 human leukemia. Cancer Res., 46, 3330-3333.
OSHEROFF, N. (1989). Biochemical basis for the interactions of type
I and type II topoisomerases with DNA. Pharmacol. Ther., 41,
223-241.
PATEL, S. & FISHER, L.M. (1993). Novel selection and genetic charac-
terisation of an etoposide-resistant human leukaemic CCRF-
CEM cell line. Br. J. Cancer, 67, 456-463.
PER, S.R., MATTERN, M.R., MIRABELLI, C.K., DRAKE, F.H., JOHN-
SON, R.K. & CROOKE, S.T. (1987). Characterization of a subline
of P388 leukemia resistant to amsacrine: evidence of altered
topoisomerase II function. Mol. Pharmacol., 32, 17-25.
POLITI, P.M., ARNOLD, S.T., FELSTED, R.L. & SINHA, B.K. (1990).
P-glycoprotein-independent mechanism of resistance to VP-16 in
multidrug-resistant tumor cell lines: pharmacokinetic and photo-
affinity labeling studies. Mol. Pharmacol., 37, 790-796.
POMMIER, Y., SCHWARTZ, R.E., KOHN, K.W. & ZWELLING, L.A.
(1984). Formation and rejoining of deoxyribonucleic acid double-
strand breaks induced in isolated cell nuclei by antineoplastic
intercalating agents. Biochemistry, 23, 3194-3201.
POMMIER, Y., SCHWARTZ, R.E., ZWELLING, L.A., KERRIGAN, D.,
MATTrERN, M.R., CHARCOSSET, J.-Y., JACQUENIN-SARLON, A.
& KOHN, K.W. (1986a). Reduced formation of protein-associated
DNA strand breaks in Chinese hamster cells resistant to
topoisomerase inhibitors. Cancer Res., 46, 611 -616.
POMMIER, Y., KERRIGAN, D., SCHWARTZ, R.E., SWACK, J.A. &
MCCURDY, A. (1986b). Altered DNA topoisomerase II activity in
Chinese hamster cells resistant to topoisomerase II inhibitors.
Cancer Res., 46, 3075-3081.VP-16 RESISTANCE AND ALTERED DNA TOPOISOMERASE II 697
RITKE, M.K. & YALOWICH, J.C. (1993). Altered gene expression in
human leukemia K562 cells selected for resistance to etoposide
(VP-16). Biochem. Pharmacol., 46, 2007-2020.
RITKE, M.K., ALLAN, W.P., GUNDUZ, N.N. & YALOWICH, J.C.
(1993). Reduced phosphorylation of topoisomerase II in etopo-
side-resistant human leukemia K562 cells. Mol. Pharmacol. (sub-
mitted).
ROBERTS, D., FOGLESONG, P.D., PARGANAS, E. & WIGGINS, L.
(1989). Reduced formation of lesions in the DNA of a multidrug-
resistant L1210 subline selected for teniposide resistance. Cancer
Chemother. Pharmacol., 23, 161-168.
ROSS, W.E., GLAUBIGER, D. & KOHN, K.W. (1979). Qualitative and
quantitative aspects of intercalator-induced DNA strand breaks.
Biochim. Biophys. Acta, 562, 41-50.
SAHAI, B.M. & KAPLAN, J.G. (1986). A quantitive decatenation assay
for type II topoisomerases. Anal. Biochem., 156, 364-379.
SAHYOUN, N., WOLF, M., BESTERMAN, J., HSIEH, T.-S., SANDER,
M., LEVINE, H., CHANG, K.-J. & CUATRECASAS, P. (1986). Pro-
tein kinase C phosphorylates topoisomerase II: topoisomerase
activation and its possible role in phorbol ester-induced
differentiation of HL-60 cells. Proc. Natl Acad. Sci. USA, 83,
1603-1607.
SAIJO, M., UI, M. & ENOMOTO, T. (1992). Growth state and cell cycle
dependent phosphorylation of DNA topoisomerase II in Swiss
3T3 cells. Biochemistry, 31, 359-363.
SAIJO, M., ENOMOTO, T., HANAOKA, F. & UI, M. (1990). Purification
and characterization of type II DNA topoisomerase from mouse
FM3A cells: phosphorylation of topoisomerase II and mod-
ification of its activity. Biochemistry, 29, 583-590.
SINKULE, J.A. & EVANS, W.E. (1984). High performance liquid
chromatographic analysis of the semisynthetic epipodophyllotox-
ins teniposide and etoposide using electrochemical detection. J.
Pharmaceut. Sci., 73, 164-168.
SUGAWARA, I., IWAHASHI, T., OKAMOTO, K., SUGIMOTO, Y.,
EKIMOTO, H., TSURUO, T., IKEUCHI, T. & MORI, S. (1991).
Characterization of an etoposide-resistant human K562 cell line,
K/eto. Jpn. J. Cancer Res., 82, 1035-1043.
SULLIVAN, D.M., LATHAM, M.D., ROWE, T.C. & ROSS, W.E. (1989).
Purification and characterization of an altered topoisomerase II
from a drug-resistant Chinese hamster ovary cell line. Bio-
chemistry, 28, 5680-5687.
SULLIVAN, D.M., ESKILDSEN, L., GROOM, K.R., WEBB, C.D.,
LATHAM, M.D., MARTIN, A.W., WELLHAUSEN, S.R., KROEGER,
P.E. & ROWE, T.C. (1993). Topoisomerase II activity involved in
cleaving DNA into topological domains is altered in a multiple
drug-resistant chinese hamster ovary cell line. Mol. Pharmacol.,
43, 207-216.
TAKANO, H., KOHNO, K., ONO, M., UCHIDA, Y. & KUWANO, M.
(1991). Increased phosphorylation of DNA topoisomerase II in
etoposide-resistant mutants of human cancer KB cells. Cancer
Res., 51, 3951-3957.
TEWEY, K.M., ROWE, T.C., YANG, L., HALLIGAN, B.D. & LIU, L.F.
(1984a). Adriamycin-induced DNA damage mediated by mam-
malian DNA topoisomerase II. Science, 226, 466-468.
TEWEY, K.M., CHEN, G.L., NELSON, E.M. & LIU, L.F. (1984b). Inter-
calating antitumor drugs interfere with the breakage-reunion
reaction of mammalian DNA topoisomerase II. J. Biol. Chem.,
259, 9182-9187.
TOWBIN, H., STAEHELIN, T. & GORDON, J. (1979). Electrophoretic
transfer of proteins from polyacrylamide gels to nitrocellulose
sheets: procedures and some applications. Proc. Nati Acad. Sci.
USA, 76, 4350-4354.
TSAI-PFLUGFELDER, M., LIU, L.F., LIU, A.A., TEWEY, K.M.,
WHANG-PENG, J., KNUTSEN, T., HUEBER, K., CROCE, C.M. &
WANG, J.C. (1988). Cloning and sequencing of cDNA encoding
human DNA topoisomerase II and localization of the gene to
chromosome region 17q21-22. Proc. Natl Acad. Sci. USA, 85,
7177-7181.
WANG, J.C. (1985). DNA topoisomerases. Annu. Rev. Biochem., 54,
665-697.
WEBB, C.D., LATHAN, M.D., LOCK,, R.B. & SULLIVAN, D.M. (1991).
Attenuated topoisomerase II content directly correlates with a
low level of drug resistance in a chinese hamster ovary cell line.
Cancer Res., 51, 6542-6549.
WEBB, C.F., ENEFF, K.L. & DRAKE, F.H. (1993). A topoisomerase
II-like protein is part of an inducible DNA-binding protein com-
plex that binds 5' of an immunoglobulin promoter. Nucleic Acids
Res., 21, 4363-4368.
WOESSNER, R.D., MATTERN, M.R., MIRABELLI, C.K.. JOHNSON,
R.K. & DRAKE, F.H. (1991). Proliferation- and cell cycle-
dependent differences in expression of the 170 kilodalton and 180
kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell
Growth Different., 2, 209-214.
YALOWICH, J.C. (1987). Effects of microtubule inhibitors on
etoposide accumulation and DNA damage in human K562 cells
in vitro. Cancer Res., 47, 1010-1015.
YALOWICH, J.C. & GOLDMAN, I.D. (1984). Analysis of the inhibitory
effects of VP-16-213 (etoposide) and podophyllotoxin on
thymidine transport and metabolism in Ehrlich ascites tumor cells
in vitro. Cancer Res., 44, 984-989.
ZHANG, H., D'ARPA, P. & LIU, L.F. (1990). A model for tumor cell
killing by topoisomerase poisons. Cancer Cells, 2, 23-27.
ZWELLING, L.A. (1985). DNA topoisomerase II as a target of
antineoplastic drug therapy. Cancer Metastasis Rev., 4, 263-276.
ZWELLING, L.A., HINDS, M., CHAN, D., MAYES, L., LAN SIE, K.,
PARKER, E., SILBERMAN, L., RADCLIFFE, A., BERAN, M. &
BLICK, M. (1989). Characterization of an amsacrine-resistant line
of human leukemia cells: evidence for a drug-resistant form of
topoisomerase II. J. Biol. Chem., 264, 16411-16420.